BSECompany Update4d ago · 27 Jul 2026, 06:26 pm
Intimation for Receipt of Request for Reclassification of Shareholder Category
Sun Pharma Advanced Research Company Ltd · 532872
✦ AI SummaryPromoter Reclassif.
Sun Pharma Advanced Research Company Ltd has received requests from two shareholders, Sudhir Vrundavandas Valia and his family members, to reclassify their status from 'Promoter Group' to 'Public' category under SEBI regulations.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk2/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sun Pharma Advanced Research Company Ltd - 532872 - Intimation For Receipt Of Requests For Reclassification Of Shareholder Category
Attachments (1)
📄pdf
Download →
4ae0e893-533b-461c-84e3-8f492ed372ae.pdf
View document text
SPARC/Sec/SE/2026-27/24 July 27, 2026
National Stock Exchange of India Ltd., BSE Limited,
Exchange Plaza, 5th Floor, Market Operations Dept.
Plot No. C/1, G Block, P. J. Towers,
Bandra Kurla Complex, Dalal Street,
Bandra (East), Mumbai – 400 051. Mumbai - 400 001.
Scrip Symbol: SPARC Scrip Code: 532872
Dear Sir/Madam,
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015- Receipt of requests for reclassification of shareholder category
This is to inform that the Company has received requests on July 27, 2026 from the below-
mentioned persons, presently classified as members of the Promoter Group, seeking
reclassification of their status from ‘Promoter Group’ category to ‘Public’ category under
Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
(“Listing Regulations”):
Sr. Name of Shareholder No. of shares held Percentage (%) of
No. Shares held
1 Mr. Sudhir Vrundavandas Valia 1 8 , 3 3 , 9 5 1 0 . 5 7
2 Mrs. Raksha Sudhir Valia 41,45,231 1.28
3 Mrs. Krishna Vrundavandas Valia - -
Total 59,79,182 1.85
The aforesaid requests will be examined by the Company in accordance with the applicable
provisions of the Listing Regulations and shall be placed before the Board of Directors for its
consideration in due course. Subject to the approval of the Board and completion of the
prescribed process, the Company will take necessary steps, including submission of the
application to the stock exchanges.
This intimation is being made in compliance with the provisions of the Listing Regulations.
For Sun Pharma Advanced Research Company Ltd.
Kajal Damania
Company Secretary and Compliance Officer